These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1300 related items for PubMed ID: 14967716

  • 1. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mügge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA, ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group.
    Circulation; 2004 Mar 02; 109(8):997-1003. PubMed ID: 14967716
    [Abstract] [Full Text] [Related]

  • 2. Use of subcutaneous enoxaparin compared to intravenous heparin and oral phenprocoumon in the setting of cardioversion--the ACE study (Anticoagulation in Cardioversion using Enoxaparin).
    Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mügge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA, Anticoagulation in Cardioversion using Enoxaparin Study Group.
    Card Electrophysiol Rev; 2003 Dec 02; 7(4):382-6. PubMed ID: 15071260
    [Abstract] [Full Text] [Related]

  • 3. Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Schmidt-Lucke C, Paar WD, Stellbrink C, Nixdorff U, Hofmann T, Meurer J, Grewe R, Daniel WG, Hanrath P, Mügge A, Klein HU, Schmidt-Lucke JA.
    Thromb Res; 2007 Dec 02; 119(1):27-34. PubMed ID: 16443257
    [Abstract] [Full Text] [Related]

  • 4. Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany.
    Schädlich PK, Schmidt-Lucke C, Huppertz E, Lehmacher W, Nixdorff U, Stellbrink C, Brecht JG.
    Am J Cardiovasc Drugs; 2007 Dec 02; 7(3):199-217. PubMed ID: 17610347
    [Abstract] [Full Text] [Related]

  • 5. The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicentre study.
    Klein AL, Jasper SE, Katz WE, Malouf JF, Pape LA, Stoddard MF, Apperson-Hansen C, Lieber EA, ACUTE II Steering and Publications Committe for the ACUTE II Investigators.
    Eur Heart J; 2006 Dec 02; 27(23):2858-65. PubMed ID: 17098762
    [Abstract] [Full Text] [Related]

  • 6. Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion.
    Bechtold H, Gunzenhauser D, Sawitzki H, Fung S, Janssen D.
    Z Kardiol; 2003 Jul 02; 92(7):532-9. PubMed ID: 12883837
    [Abstract] [Full Text] [Related]

  • 7. Health status outcomes after cardioversion for atrial fibrillation: results from the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Trial.
    Elliott DJ, Zhao L, Jasper SE, Lieber EA, Klein AL, Weintraub WS.
    Am Heart J; 2008 Aug 02; 156(2):374.e1-6. PubMed ID: 18657673
    [Abstract] [Full Text] [Related]

  • 8. Low molecular weight heparin for prevention of thromboembolic complications in cardioversion--rationale and design of the ACE study (Anticoagulation in Cardioversion using Enoxaparin).
    Stellbrink C, Hanrath P, Nixdorff U, Hofmann T, Lehmacher W, Kühle K, Fetsch T, Grewe R, Schmidt-Lucke JA, Anticoagulation in Cardioversion using Enoxaparin Study Group.
    Z Kardiol; 2002 Mar 02; 91(3):249-54. PubMed ID: 12001541
    [Abstract] [Full Text] [Related]

  • 9. Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study).
    Sorino M, Colonna P, De Luca L, Carerj S, Oliva E, De Tommasi SM, Conti U, Iacopi F, D'Agostino C, D'Amato N, Pettinati G, Montericcio V, Cualbu A, De Luca I.
    J Cardiovasc Med (Hagerstown); 2007 Dec 02; 8(12):1034-42. PubMed ID: 18163016
    [Abstract] [Full Text] [Related]

  • 10. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.
    Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW, THE-PRINCE Study Group.
    Am Heart J; 2003 Apr 02; 145(4):614-21. PubMed ID: 12679756
    [Abstract] [Full Text] [Related]

  • 11. Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
    Bui HT, Krisnaswami A, Le CU, Chan J, Shenoy BN.
    Am J Cardiol; 2009 Nov 15; 104(10):1429-33. PubMed ID: 19892063
    [Abstract] [Full Text] [Related]

  • 12. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation.
    Hoppensteadt D, Fareed J, Klein AL, Jasper SE, Apperson-Hansen C, Lieber EA, Katz WE, Malouf JF, Stoddard MF, Pape LA, Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Investigators.
    Am J Cardiol; 2008 Oct 01; 102(7):842-6. PubMed ID: 18805108
    [Abstract] [Full Text] [Related]

  • 13. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
    Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR, STEEPLE Investigators.
    N Engl J Med; 2006 Sep 07; 355(10):1006-17. PubMed ID: 16957147
    [Abstract] [Full Text] [Related]

  • 14. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
    Bergmann JF, Neuhart E.
    Thromb Haemost; 1996 Oct 07; 76(4):529-34. PubMed ID: 8902991
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ, Califf RM.
    Am Heart J; 2006 Dec 07; 152(6):1042-50. PubMed ID: 17161049
    [Abstract] [Full Text] [Related]

  • 16. [Anticoagulation in cardioversion of atrial fibrillation. Current status and outlook for the future].
    Schimpf T, Stellbrink C.
    Med Klin (Munich); 2003 Feb 15; 98(2):91-5. PubMed ID: 12601533
    [Abstract] [Full Text] [Related]

  • 17. [Anticoagulation with low molecular weight heparins within the framework of cardioversion for atrial fibrillation].
    Tebbe U.
    Dtsch Med Wochenschr; 2007 Sep 15; 132(39):2033-6. PubMed ID: 17882745
    [No Abstract] [Full Text] [Related]

  • 18. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F.
    N Engl J Med; 1997 Aug 14; 337(7):447-52. PubMed ID: 9250846
    [Abstract] [Full Text] [Related]

  • 19. Cost in the use of enoxaparin compared with unfractionated heparin in patients with atrial fibrillation undergoing a transesophageal echocardiography-guided cardioversion (from Assessment of Cardioversion using Transesophageal Echocardiography [ACUTE] II randomized multicenter study).
    Zhao L, Zhang Z, Kolm P, Jasper S, Lewis C, Klein A, Weintraub W, ACUTE II Investigators.
    Am J Cardiol; 2008 Feb 01; 101(3):338-42. PubMed ID: 18237596
    [Abstract] [Full Text] [Related]

  • 20. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
    Califf RM, Petersen JL, Hasselblad V, Mahaffey KW, Ferguson JJ.
    Am Heart J; 2005 Apr 01; 149(4 Suppl):S91-9. PubMed ID: 16124953
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.